Replay LSI2021 Emerging Medtech Summit

Play Now
innovation hub

TESARO is Profiled in this Database

Updated At 29 Jul, 2011

Start Free 7 Day Trial Now
Partial description of this company
Compounds for oncology indications, including: 1-the prevention of A) chemotherapy-induced nausea and vomiting (CINV), B) post-operative nausea and vomiting (PONV), and C) chronic cough and 2-treatment for patients with non-small cell lung cancer (NSCLC) whose tumors express an Anaplastic Lymphoma Kinase (ALK) fusion protein

Start Trial Get Full Profile

There’s no risk. Start your trial today to see profiles of TESARO plus 4982 other startups.

Start Free 7 Day Trial Now

Learn More About TESARO

Technology/product details

Revenue projections

Capital raised to date

Growth strategy


Our Clients